Follicular Lymphoma Clinical Trials

• Gender: No restrictions; age ≥18 years.

• Diagnosis: Histologically confirmed CD20-positive follicular lymphoma (FL), Grade 1, 2, or 3A, per 2016 WHO classification. All patients must provide sufficient archived or fresh tumor tissue samples for immunohistochemical (IHC) analysis.

• Disease Stage \& Treatment Need:

• Stage III or IV disease, or Stage II with bulky disease, meeting at least one of the following criteria:

• a) Bulky disease: Lymph node or extranodal (excluding spleen) mass with maximum diameter ≥7 cm.

• b) Local symptoms or organ dysfunction due to progressive lymphadenopathy or extranodal tumor mass.

• c) B symptoms (fever, night sweats, or unintentional weight loss \>10% of body weight within ≤6 months).

• d) Symptomatic extranodal involvement (e.g., pleural/peritoneal effusion).

• e) Cytopenias due to bone marrow infiltration (hemoglobin \<10 g/dL, absolute neutrophil count \[ANC\] \<1.0×10⁹/L, platelets \<100×10⁹/L).

• f) Involvement of ≥3 lymph nodes, each ≥3 cm in diameter.

• g) Symptomatic splenomegaly.

• Prior Therapy: No prior systemic therapy for FL.

• ECOG Performance Status: ≤2.

• Measurable Disease: At least one measurable lesion (\>2 cm in longest diameter by CT/MRI).

• Life Expectancy: ≥6 months.

• Adequate Organ Function:

• a) ANC ≥1.0×10⁹/L (without growth factor support).

• b) Platelets ≥50×10⁹/L (untransfused within 7 days).

• c) Total bilirubin (TBIL) ≤1.5×ULN.

• d) ALT/AST ≤3×ULN.

• e) Creatinine clearance ≥30 mL/min (calculated by modified Cockcroft-Gault formula).

• Contraception: Men and women of childbearing potential must agree to use highly effective contraception during the study and for 4 weeks after treatment discontinuation.

• Informed Consent: Patients must voluntarily participate and sign informed consent forms (ICF).